Aroa Biosurgery Past Earnings Performance
Past criteria checks 0/6
Aroa Biosurgery has been growing earnings at an average annual rate of 11.5%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 29.2% per year.
Key information
11.5%
Earnings growth rate
79.4%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 29.2% |
| Return on equity | -11.2% |
| Net Margin | -15.4% |
| Next Earnings Update | 25 Nov 2024 |
Recent past performance updates
Recent updates
We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Nov 13
Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aug 22Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
Jun 12Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Mar 25Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Jan 30Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
Nov 14Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Nov 02Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Oct 25We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
May 13Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results
May 26An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued
Mar 22Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?
Feb 24Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)
Feb 24Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price
Dec 16
Revenue & Expenses Breakdown
How Aroa Biosurgery makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 69 | -11 | 62 | 9 |
| 31 Dec 23 | 67 | -9 | 59 | 9 |
| 30 Sep 23 | 66 | -8 | 56 | 10 |
| 30 Jun 23 | 65 | -4 | 52 | 10 |
| 31 Mar 23 | 63 | 0 | 48 | 11 |
| 31 Dec 22 | 57 | -1 | 42 | 11 |
| 30 Sep 22 | 51 | -2 | 37 | 11 |
| 30 Jun 22 | 45 | -5 | 34 | 10 |
| 31 Mar 22 | 40 | -8 | 31 | 8 |
| 31 Dec 21 | 35 | -10 | 28 | 8 |
| 30 Sep 21 | 31 | -11 | 26 | 7 |
| 30 Jun 21 | 27 | -15 | 24 | 7 |
| 31 Mar 21 | 22 | -19 | 22 | 6 |
| 31 Dec 20 | 22 | -19 | 21 | 6 |
| 30 Sep 20 | 21 | -19 | 20 | 5 |
| 30 Jun 20 | 23 | -12 | 18 | 5 |
| 31 Mar 20 | 25 | -6 | 17 | 5 |
| 31 Mar 19 | 24 | 1 | 12 | 5 |
| 31 Mar 18 | 11 | -1 | 4 | 3 |
Quality Earnings: ARX is currently unprofitable.
Growing Profit Margin: ARX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARX is unprofitable, but has reduced losses over the past 5 years at a rate of 11.5% per year.
Accelerating Growth: Unable to compare ARX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.7%).
Return on Equity
High ROE: ARX has a negative Return on Equity (-11.19%), as it is currently unprofitable.